Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975716 | 0.93 | KCNH2 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL22958985 | 0.93 | KCNH2 (1.00) | KCNH2TLR8TLR7 | |
| SCHEMBL15502379 | 0.92 | KCNH2 (0.84) | KCNH2TLR8CYP2D6TLR7 | |
| SCHEMBL13975906 | 0.89 | KCNH2 (0.80) | KCNH2TLR8TLR7 | |
| SCHEMBL19722983 | 0.87 | KCNH2 (1.00) | KCNH2TLR8CYP2D6DRD1HTR2A | |
| SCHEMBL15502428 | 0.87 | KCNH2 (1.00) | KCNH2TLR8CYP2D6DRD1HTR2A | |
| SCHEMBL15502389 | 0.86 | KCNH2 (0.75) | KCNH2TLR8CYP2D6DRD1HTR2A | |
| SCHEMBL24384587 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7 | |
| SCHEMBL13975908 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7 | |
| SCHEMBL22958997 | 0.85 | KCNH2 (0.85) | KCNH2TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-8916575-B2 | Quinazoline derivatives for the treatment of viral infections and further diseases | JANSSEN R&D IRELAND (IE) | 2014-12-23 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2014-03-13 | — | — | US | disclosed |
| WO-2012156498-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN R&D IRELAND (IE) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073642-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | TLR3, TLR5, TLR4 | KCNH2 2625/4885TLR8 9/4885CYP2D6 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.